FOR US HEALTHCARE PROFESSIONALS ONLY

For adults living with schizophrenia
Repeated relapses and cycles of failure on oral antipsychotics can shatter lives

SYMPTOM STABILITY

CAN’T WAIT

There is only 1 INVEGA SUSTENNA^®

See how INVEGA SUSTENNA^® can provide
patients with superior symptom control today

Actor Portrayal.

Trust what you know

Prescribe INVEGA SUSTENNA^® today

SUPERIORITY

INVEGA SUSTENNA^® is the only* LAI with proven superiority vs a group of orals^1,2†

RELIABILITY

INVEGA SUSTENNA^® has a proven efficacy and safety profile, prescribed by mental health providers for >15 years^1-5

AFFORDABILITY

INVEGA SUSTENNA^® is widely covered‡ and may cost as low as $0 per month for government-insured patients^{6,7‡§||¶#}**

*Only Johnson & Johnson conducted these clinical trials.

LAI=long-acting injectable.

^†The oral antipsychotics accounted for 74% of oral schizophrenia treatment during the study period.⁸ Primary endpoint: Time to first treatment failure. The 5 most common AEs in the INVEGA SUSTENNA^® group were: injection-site pain (18.6%), insomnia (16.8%), weight increase (11.9%), akathisia (11.1%) and anxiety (10.6%).²

Rapid disease progression occurs within the first
3-5 years
post diagnosis^9,10

Delayed symptom control can lead to a dangerous downward trend of repeated relapses, worsening symptoms, and increasing disability for adults with schizophrenia^10,11

Achieving effective symptom control earlier after diagnosis is critical^9-11

Effective and sustained symptom control is the foundation of a comprehensive treatment plan, with medication being 1 part of a multipronged approach.^9,10

Earlier intervention with INVEGA SUSTENNA^® can help delay time to relapse^1-3

It's never too late to offer patients the consistent medication delivery of

once-monthly

INVEGA SUSTENNA^®.^1-3

Did you know adults with schizophrenia are:

more likely

to experience a negative housing change, such as becoming homeless, after 1 relapse¹²

more likely

to be incarcerated after experiencing 1 relapse¹²

66.2^%

more likely

to be unemployed with 1 relapse experience vs patients with no relapses¹²

A comprehensive treatment plan, which could include cognitive behavioral therapy and psychosocial services, can help patients address these challenges.^9,10

Help avoid
cycles of relapse
associated with daily orals with INVEGA SUSTENNA^®—the #1 prescribed LAI.^2,3,13

In a 15-month study with
a real-world^†† design:

INVEGA SUSTENNA^® was studied vs a group of 7 commonly prescribed oral antipsychotics^1,2‡‡

See comparative results

In a 24-month
international^§§ study:

INVEGA SUSTENNA^® was studied vs a group of common oral antipsychotics in adults diagnosed with schizophrenia within 1-5 years⁷

See results in recently diagnosed patients

In a post hoc analysis of
these 2 studies:

The risk of relapse with INVEGA SUSTENNA^® in adult patients was evaluated based on time since diagnosis (ranging from 0-5 years)¹⁴

See earlier use analysis

INVEGA SUSTENNA^® was evaluated in 4 short-term and 1 longer-term placebo-controlled trials¹

See pivotal studies

††Real-world was defined by patient selection and clinically meaningful outcome measures.²

‡‡The 7 oral antipsychotics included in the comparative arm accounted for 74% of oral schizophrenia treatment during the study period.⁸

§§The study was conducted in 26 countries, excluding the United States.³

‡Widely covered is defined as >65% number of covered lives. Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of February 2025. Collected as of February 2025 and may change.

§This information is not a promise of coverage or payment. It is not intended to give reimbursement advice or increase reimbursement by any payer. Legal requirements and plan information can be updated frequently. Contact the plan for more information about current coverage, reimbursement policies, restrictions, or requirements that may apply.

||The Medicaid out-of-pocket cost range for generic oral antipsychotics in 2019 was $0.00–$343.06 and the range for INVEGA SUSTENNA^® was $0.00–$348.41. 95% of patients on generic oral antipsychotics paid $3.13 or less, and 95% of patients on INVEGA SUSTENNA^® paid $3.36 or less.¹⁵

¶The Medicare Part D Low-Income Subsidy (LIS) out-of-pocket cost range for generic oral antipsychotics in 2019 was $0.00–$40.80 and the range for all second-generation long-acting injectables (eg, INVEGA SUSTENNA^®) was $0.00–$34.00.⁷

#Medicare Part D LIS patients who paid $0 were institutionalized. Noninstitutionalized patients paid as low as $15.20 per month.⁷

**See the Access and Affordability page for more information.

References: 1. INVEGA SUSTENNA^® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 3. Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1-3):393-399. 4. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. 5. Center for Drug Evaluation and Research. Approval letter. July 31, 2009. Accessed November 19, 2025. www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022264s000Approv.pdf. 6. Lin D, Pilon D, Benson C, et al. PMH7: Assessment of patient out-of-pocket costs for antipsychotic treatments among Medicaid beneficiaries with schizophrenia. Poster presented at: ISPOR 2021; May 17-20, 2021; Virtual. 7. Li P, Benson C, Zhi Geng Z, et al. Out-of-pocket costs for long-acting injectable and oral antipsychotics among full Low-Income Subsidy (LIS) Medicare beneficiaries with schizophrenia. Poster presented at: Psych Congress Elevate. June 3-5, 2022. Las Vegas, NV. 8. Data on file. Janssen Pharmaceuticals, Inc. 9. Birchwood M. Early intervention and sustaining the management of vulnerability. Aust N Z J Psychiatry. 2000;34 Suppl:S181-184. 10. Tandon R, Nasrallah H, Akbarian S, et al. The schizophrenia syndrome, circa 2024: what we know and how that informs its nature. Schizophr Res. 2024;264:1-28. 11. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches [published correction appears in Biol Psychiatry. 2002;51(4):346]. Biol Psychiatry. 2001;50(11):884-897. 12. Lin D, Joshi K, Keenan A, et al. Associations between relapses and psychosocial outcomes in patients with schizophrenia in real-world settings in the United States. Front Psychiatry. 2021;12:695672. 13. Data on file. Janssen Pharmaceuticals, Inc. 14. Sajatovic M, Doring M, Lopena OJ, et al. Earlier use of long-acting injectable paliperidone palmitate once-monthly versus oral antipsychotics in patients with schizophrenia: an integrated patient-level meta-analysis of the PROSIPAL and PRIDE studies. Neuropsychiatr Dis Treat. 2024;20:2227-2235. 15. Data on file. Janssen Pharmaceuticals, Inc.

SYMPTOM STABILITY

CAN’T WAIT

Trust what you know

Prescribe INVEGA SUSTENNA® today

SUPERIORITY

RELIABILITY

AFFORDABILITY

Rapid disease progression occurs within the first 3-5 years post diagnosis9,10

Earlier intervention with INVEGA SUSTENNA® can help delay time to relapse1-3

Did you know adults with schizophrenia are:

more likely

more likely

more likely

Help avoid cycles of relapse associated with daily orals with INVEGA SUSTENNA®—the #1 prescribed LAI.2,3,13

Prescribe INVEGA SUSTENNA^® today

Rapid disease progression occurs within the first
3-5 years
post diagnosis^9,10

Earlier intervention with INVEGA SUSTENNA^® can help delay time to relapse^1-3

Help avoid
cycles of relapse
associated with daily orals with INVEGA SUSTENNA^®—the #1 prescribed LAI.^2,3,13